Europe Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021-2027

The Europe Benign Prostatic Hyperplasia Therapeutics Market is expected to witness market growth of 3.9% CAGR during the forecast period (2021-2027).

BPH is neither a malignancy nor a cause of prostate cancer. BPH, on the other hand, can be inconvenient and, in a number of instances, can lead to bladder obstruction. It appears to be a natural part of the aging process, affecting men over the age of 40. Benign prostate hyperplasia is characterized by the presence of discrete nodules in the periurethral zone of the prostate gland.

To treat BPH symptoms, drugs such as alpha-blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors are employed. These treatments relax the smooth bladder muscles or reduce the abnormal prostate growth. The prostate's grasp on the urethra loosens as bladder muscles relax, enabling urine to flow more freely. Prostate shrinking, on the other hand, lessens the pressure produced by the prostate on the urethra, allowing urine to flow freely.

Despite the fact that 40% of men over the age of 60 have an enlarged prostate, a new poll published by the European Association of Urology (EAU) has shown that awareness of prostate health is disturbingly low among men over 50. Only 38% of respondents correctly identified the disease (beneficial prostate enlargement (BPE) or hyperplasia (BPH)). The main purpose of a healthy prostate, which is around the size of a walnut, is to produce prostatic fluid, which is used to transport sperm. Despite the fact that it grows slowly as men age, just one in six (17%) respondents correctly said that symptoms associated with an enlarged prostate are not a "typical" indicator of aging.

The Germany market dominated the Europe Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $481.1 million by 2027. The UK market is expected to experience a CAGR of 3.1% during (2021 - 2027). Additionally, The France market is anticipated to grow a CAGR of 4.6% during (2021 - 2027).

Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study

Market Segments Covered in the Report:

By Therapy

• Mono Drug Therapy
• Combination Drug Therapy

By Therapeutics Class

• Alpha Blockers
• 5- alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• GlaxoSmithKline PLC (GSK)
• Astellas Pharma, Inc.
• Eli Lilly and Company
• Allergan PLC (AbbVie)
• Merck Group (Merck Sharp & Dohme Corp.)
• Boehringer Ingelheim International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Sanofi S.A.
• Pfizer, Inc.
• Abbott Laboratories

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free